Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Oct;34(10):2091-2097.
doi: 10.1007/s11606-019-05189-y. Epub 2019 Jul 31.

Understanding Long-Term Cancer Survivors' Preferences for Ongoing Medical Care

Tenbroeck G Smith  1 , Sara Strollo  2 , Xin Hu  3 , Craig C Earle  4 , Corinne R Leach  2 , Larissa Nekhlyudov  5
Affiliations

Understanding Long-Term Cancer Survivors' Preferences for Ongoing Medical Care

Tenbroeck G Smith et al. J Gen Intern Med. 2019 Oct.

Abstract

Background: Due to risk for treatment-related late effects and concerns about cancer recurrence, long-term cancer survivors have unique medical needs. Survivors' preferences for care may influence adherence and care utilization.

Objective: To describe survivors' preferences for care and factors associated with preferred and actual care.

Design: Cross-sectional analysis of participants in a longitudinal study using mailed questionnaires.

Participants: Survivors of ten common cancers (n = 2,107, mean years from diagnosis 8.9).

Main measures: (1) Survivors' preferences for primary care physician (PCP) and oncologist responsibilities across four types of care: cancer follow-up, cancer screening, preventive health, and comorbid conditions. (2) Survivor-reported visits to PCPs and oncologists.

Key results: The response rate was 42.1%. Most long-term survivors preferred PCPs and oncologists share care for cancer follow-up (63%) and subsequent screening (65%), while preferring PCP-led preventive health (77%) and comorbid condition (83%) care. Most survivors (88%) preferred oncologists involved in cancer follow-up care, but only 60% reported an oncologist visit in the previous 4 years, and 96% reported a PCP visit in the previous 4 years. In multivariable regressions, those with higher fear of cancer recurrence were less likely to prefer PCP-led cancer follow-up care (OR = 0.96, CI = 0.93-0.98), as did survivors with advanced cancer stage (OR = 0.56, CI = 0.39-0.79). Those with higher fear of recurrence (OR = 1.03, CI = 1.01-1.04) or who preferred oncologist-led cancer follow-up care (OR = 2.08, CI = 1.63-2.65) had greater odds of seeing an oncologist in the last 4 years.

Conclusions: Most cancer survivors preferred PCPs and oncologists share care for cancer follow-up and screening, yet many had not seen an oncologist recently. Survivors preferred PCP-led care for other preventive services and management of comorbid conditions. These findings highlight the important role PCPs could play in survivor care, suggesting the need for PCP-oriented education and health system policies that support high-quality PCP-led survivor care.

Keywords: cancer survivorship; fear of cancer recurrence; oncology; patient-centered care; primary care.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they do not have a conflict of interest.

Figures

Figure 1
Figure 1
Long-term survivors’ physician preferences for four aspects of care.
See this image and copyright information in PMC

References

    1. Miller KD, Siegel RL, Lin CC, et al. Cancer treatment and survivorship statistics, 2016. CA Cancer J Clin. 2016;66(4):271–289. - PubMed
    1. Cancer Treatment & Survivorship Facts & Figures 2016–2017. Atlanta: American Cancer Society;2016.
    1. Mayer DK, Nasso SF, Earp JA. Defining cancer survivors, their needs, and perspectives on survivorship health care in the USA. Lancet Oncol. 2017;18(1):e11–e18. - PubMed
    1. Mariotto AB, Rowland JH, Ries LA, Scoppa S, Feuer EJ. Multiple cancer prevalence: a growing challenge in long-term survivorship. Cancer Epidemiol Biomarkers Prev. 2007;16(3):566–571. - PubMed
    1. Curigliano G, Cardinale D, Dent S, et al. Cardiotoxicity of anticancer treatments: Epidemiology, detection, and management. CA Cancer J Clin. 2016;66(4):309–325. - PubMed

Publication types